

# Seiya Yamayoshi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1325796/publications.pdf>

Version: 2024-02-01

86  
papers

6,206  
citations

136950

32  
h-index

82547

72  
g-index

96  
all docs

96  
docs citations

96  
times ranked

8526  
citing authors

#	ARTICLE	IF	CITATIONS
1	Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16587-16595.	7.1	912
2	SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature, 2022, 603, 687-692.	27.8	475
3	Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nature Medicine, 2009, 15, 798-801.	30.7	457
4	Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature, 2022, 602, 300-306.	27.8	428
5	Characterization of H7N9 influenza A viruses isolated from humans. Nature, 2013, 501, 551-555.	27.8	371
6	Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. New England Journal of Medicine, 2022, 386, 995-998.	27.0	301
7	Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. New England Journal of Medicine, 2022, 386, 1475-1477.	27.0	240
8	Contributions of Two Nuclear Localization Signals of Influenza A Virus Nucleoprotein to Viral Replication. Journal of Virology, 2007, 81, 30-41.	3.4	194
9	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature, 2022, 607, 119-127.	27.8	174
10	Comparison of Rapid Antigen Tests for COVID-19. Viruses, 2020, 12, 1420.	3.3	166
11	Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14753-14758.	7.1	135
12	Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EclinicalMedicine, 2021, 32, 100734.	7.1	134
13	Current and future influenza vaccines. Nature Medicine, 2019, 25, 212-220.	30.7	132
14	Human SCARB2-Dependent Infection by Coxsackievirus A7, A14, and A16 and Enterovirus 71. Journal of Virology, 2012, 86, 5686-5696.	3.4	130
15	A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets. Cell Host and Microbe, 2017, 22, 615-626.e8.	11.0	121
16	Functional Comparison of SCARB2 and PSGL1 as Receptors for Enterovirus 71. Journal of Virology, 2013, 87, 3335-3347.	3.4	108
17	Virulence-Affecting Amino Acid Changes in the PA Protein of H7N9 Influenza A Viruses. Journal of Virology, 2014, 88, 3127-3134.	3.4	100
18	Ebola Virus Matrix Protein VP40 Uses the COPII Transport System for Its Intracellular Transport. Cell Host and Microbe, 2008, 3, 168-177.	11.0	89

#	ARTICLE	IF	CITATIONS
19	Identification of a Novel Viral Protein Expressed from the PB2 Segment of Influenza A Virus. <i>Journal of Virology</i> , 2016, 90, 444-456.	3.4	87
20	Identification of a Human SCARB2 Region That Is Important for Enterovirus 71 Binding and Infection. <i>Journal of Virology</i> , 2011, 85, 4937-4946.	3.4	79
21	Receptors for enterovirus 71. <i>Emerging Microbes and Infections</i> , 2014, 3, 1-7.	6.5	67
22	Longitudinal antibody repertoire in mild versus severe COVID-19 patients reveals immune markers associated with disease severity and resolution. <i>Science Advances</i> , 2021, 7, .	10.3	63
23	Characterization of a new SARS-CoV-2 variant that emerged in Brazil. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	63
24	Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors Fcγ3RIIA and Fcγ3RIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages. <i>MBio</i> , 2021, 12, e0198721.	4.1	57
25	Mapping of a Region of the PA-X Protein of Influenza A Virus That Is Important for Its Shutoff Activity. <i>Journal of Virology</i> , 2015, 89, 8661-8665.	3.4	55
26	A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release. <i>EBioMedicine</i> , 2017, 17, 182-191.	6.1	54
27	Gargle Lavage as a Safe and Sensitive Alternative to Swab Samples to Diagnose COVID-19: A Case Report in Japan. <i>Clinical Infectious Diseases</i> , 2020, 71, 893-894.	5.8	51
28	Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus. <i>Nature Microbiology</i> , 2019, 4, 1024-1034.	13.3	48
29	N-Terminal Acetylation by NatB Is Required for the Shutoff Activity of Influenza A Virus PA-X. <i>Cell Reports</i> , 2018, 24, 851-860.	6.4	47
30	Influenza A virus nucleoprotein is acetylated by histone acetyltransferases PCAF and GCN5. <i>Journal of Biological Chemistry</i> , 2018, 293, 7126-7138.	3.4	41
31	Amino acids substitutions in the PB2 protein of H7N9 influenza A viruses are important for virulence in mammalian hosts. <i>Scientific Reports</i> , 2015, 5, 8039.	3.3	40
32	Correlation Analysis between Gut Microbiota Alterations and the Cytokine Response in Patients with Coronavirus Disease during Hospitalization. <i>Microbiology Spectrum</i> , 2022, 10, e0168921.	3.0	37
33	Mapping of a Region of Ebola Virus VP40 That Is Important in the Production of Virus-Like Particles. <i>Journal of Infectious Diseases</i> , 2007, 196, S291-S295.	4.0	36
34	Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene. <i>Cell Host and Microbe</i> , 2018, 24, 569-578.e4.	11.0	32
35	Enhanced Replication of Highly Pathogenic Influenza A(H7N9) Virus in Humans. <i>Emerging Infectious Diseases</i> , 2018, 24, 746-750.	4.3	29
36	Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus. <i>Journal of Infectious Diseases</i> , 2018, 217, 887-896.	4.0	27

#	ARTICLE	IF	CITATIONS
37	CRISPR-Cas3-based diagnostics for SARS-CoV-2 and influenza virus. <i>IScience</i> , 2022, 25, 103830.	4.1	25
38	Scavenger Receptor B2 as a Receptor for Hand, Foot, and Mouth Disease and Severe Neurological Diseases. <i>Frontiers in Microbiology</i> , 2012, 3, 32.	3.5	24
39	Role of the GTPase Rab1b in <i>Ebolavirus</i> Particle Formation. <i>Journal of Virology</i> , 2010, 84, 4816-4820.	3.4	23
40	Identification of novel amino acid residues of influenza virus PA-X that are important for PA-X shutoff activity by using yeast. <i>Virology</i> , 2018, 516, 71-75.	2.4	23
41	Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies. <i>Scientific Reports</i> , 2017, 7, 17735.	3.3	21
42	Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. <i>Science Translational Medicine</i> , 2022, 14, eabm4908.	12.4	21
43	Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. <i>Nature Microbiology</i> , 2022, 7, 1252-1258.	13.3	20
44	Identification of Amino Acids in Marburg Virus VP40 That Are Important for Virus-Like Particle Budding. <i>Journal of Infectious Diseases</i> , 2011, 204, S871-S877.	4.0	19
45	A Novel Functional Site in the PB2 Subunit of Influenza A Virus Essential for Acetyl-CoA Interaction, RNA Polymerase Activity, and Viral Replication. <i>Journal of Biological Chemistry</i> , 2014, 289, 24980-24994.	3.4	19
46	Risk assessment of recent Egyptian H5N1 influenza viruses. <i>Scientific Reports</i> , 2016, 6, 38388.	3.3	19
47	Antibody-free digital influenza virus counting based on neuraminidase activity. <i>Scientific Reports</i> , 2019, 9, 1067.	3.3	19
48	Genetic and antigenic characterisation of influenza A(H3N2) viruses isolated in Yokohama during the 2016/17 and 2017/18 influenza seasons. <i>Eurosurveillance</i> , 2019, 24, .	7.0	18
49	The Microminipig as an Animal Model for Influenza A Virus Infection. <i>Journal of Virology</i> , 2017, 91, .	3.4	17
50	Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus. <i>Journal of Clinical Virology</i> , 2018, 108, 105-111.	3.1	17
51	Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques. <i>Journal of Infectious Diseases</i> , 2017, 216, 582-593.	4.0	16
52	Reactivity and sensitivity of commercially available influenza rapid diagnostic tests in Japan. <i>Scientific Reports</i> , 2017, 7, 14483.	3.3	15
53	The host protein CLUH participates in the subnuclear transport of influenza virus ribonucleoprotein complexes. <i>Nature Microbiology</i> , 2016, 1, 16062.	13.3	14
54	Identification of Amino Acid Residues in Influenza A Virus PA-X That Contribute to Enhanced Shutoff Activity. <i>Frontiers in Microbiology</i> , 2019, 10, 432.	3.5	13

#	ARTICLE	IF	CITATIONS
55	Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human. <i>Journal of Infection</i> , 2018, 76, 177-185.	3.3	11
56	Antigenic differences between equine influenza virus vaccine strains and Florida sublineage clade 1 strains isolated in Europe in 2019. <i>Veterinary Journal</i> , 2021, 272, 105674.	1.7	11
57	G Protein Pathway Suppressor 1 Promotes Influenza Virus Polymerase Activity by Activating the NF- $\kappa$ B Signaling Pathway. <i>MBio</i> , 2019, 10, .	4.1	11
58	A 265-Nanometer High-Power Deep-UV Light-Emitting Diode Rapidly Inactivates SARS-CoV-2 Aerosols. <i>MSphere</i> , 2022, 7, e0094121.	2.9	11
59	Strain-Specific Contribution of Eukaryotic Elongation Factor 1 Gamma to the Translation of Influenza A Virus Proteins. <i>Frontiers in Microbiology</i> , 2018, 9, 1446.	3.5	10
60	A single amino acid change in hemagglutinin reduces the cross-reactivity of antiserum against an equine influenza vaccine strain. <i>Archives of Virology</i> , 2019, 164, 2355-2358.	2.1	9
61	Baloxavir Marboxil Treatment of Nude Mice Infected With Influenza A Virus. <i>Journal of Infectious Diseases</i> , 2020, 221, 1699-1702.	4.0	9
62	Isolation and Characterization of Human Monoclonal Antibodies That Recognize the Influenza A(H1N1)pdm09 Virus Hemagglutinin Receptor-Binding Site and Rarely Yield Escape Mutant Viruses. <i>Frontiers in Microbiology</i> , 2018, 9, 2660.	3.5	8
63	Development of an Influenza Rapid Diagnostic Kit Specific for the H7 Subtype. <i>Frontiers in Microbiology</i> , 2018, 9, 1346.	3.5	8
64	Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus. <i>Viruses</i> , 2019, 11, 149.	3.3	8
65	Pathogenesis of Influenza A(H7N9) Virus in Aged Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2020, 222, 1155-1164.	4.0	8
66	Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice. <i>Communications Biology</i> , 2020, 3, 219.	4.4	8
67	Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 2183.	3.3	8
68	Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. <i>IScience</i> , 2021, , 103379.	4.1	8
69	Ebolavirus's Foibles. <i>Cell</i> , 2017, 169, 773-775.	28.9	7
70	Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil. <i>Viruses</i> , 2019, 11, 1066.	3.3	6
71	Characterization of H7N9 avian influenza viruses isolated from duck meat products. <i>Transboundary and Emerging Diseases</i> , 2020, 67, 792-798.	3.0	6
72	Sensitivity of Commercially Available Influenza Rapid Diagnostic Tests in the 2018-2019 Influenza Season. <i>Frontiers in Microbiology</i> , 2019, 10, 2342.	3.5	5

#	ARTICLE	IF	CITATIONS
73	Evaluation of seasonal influenza vaccines for H1N1pdm09 and type B viruses based on a replication-incompetent PB2-KO virus. <i>Vaccine</i> , 2017, 35, 1892-1897.	3.8	3
74	Antigenic Change in Human Influenza A(H2N2) Viruses Detected by Using Human Plasma from Aged and Younger Adult Individuals. <i>Viruses</i> , 2019, 11, 978.	3.3	3
75	Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine. <i>Vaccines</i> , 2020, 8, 215.	4.4	3
76	Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus. <i>Journal of Veterinary Medical Science</i> , 2018, 80, 1020-1024.	0.9	2
77	Emergence of SARS-CoV-2 and its outlook. <i>Global Health &amp; Medicine</i> , 2020, 2, 1-2.	1.4	2
78	Growth properties and immunogenicity of a virus generated by reverse genetics for an inactivated equine influenza vaccine. <i>Equine Veterinary Journal</i> , 2022, 54, 139-144.	1.7	2
79	Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan. <i>Internal Medicine</i> , 2022, 61, 1681-1686.	0.7	2
80	A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs. <i>Viruses</i> , 2022, 14, 562.	3.3	2
81	Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018. <i>Viruses</i> , 2019, 11, 321.	3.3	1
82	Antibody Responses to a Reverse Genetics-Derived Bivalent Inactivated Equine Influenza Vaccine in Thoroughbred Horses. <i>Journal of Equine Veterinary Science</i> , 2022, 109, 103860.	0.9	1
83	Host protein mimics viral protein to hinder infection by Ebola virus. <i>Nature</i> , 2019, 566, 190-191.	27.8	0
84	Uncovering the Anti-Ebola Repertome. <i>Cell Host and Microbe</i> , 2020, 27, 163-165.	11.0	0
85	Chimeric hPIV2/Corona-Spike Nasal Vaccine Robustly Protects the Upper and Lower Airways Against SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
86	OUP accepted manuscript. <i>Journal of Infectious Diseases</i> , 2022, , .	4.0	0